Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
Soleno Therapeutics (NASDAQ: SLNO) announced two presentations featuring their drug VYKAT™ XR (diazoxide choline) for Prader-Willi Syndrome at the upcoming ENDO 2025 conference in San Francisco. The presentations will be delivered by Dr. Ashley Shoemaker from Vanderbilt University Medical Center.
The first presentation will discuss glycemic outcomes of the drug over a 4-year period, scheduled as an oral presentation on July 14, 2025. The second presentation, in poster format, will focus on characterizing peripheral edema in patients during long-term administration over 4.5 years.
Soleno Therapeutics (NASDAQ: SLNO) ha annunciato due presentazioni dedicate al loro farmaco VYKAT™ XR (diazoxide choline) per la Sindrome di Prader-Willi, che si terranno durante la conferenza ENDO 2025 a San Francisco. Le presentazioni saranno tenute dalla Dott.ssa Ashley Shoemaker del Vanderbilt University Medical Center.
La prima presentazione, in formato orale il 14 luglio 2025, tratterà i risultati glicemici del farmaco su un periodo di 4 anni. La seconda, in formato poster, si concentrerà sulla caratterizzazione dell’edema periferico nei pazienti durante la somministrazione a lungo termine di 4,5 anni.
Soleno Therapeutics (NASDAQ: SLNO) anunció dos presentaciones sobre su medicamento VYKAT™ XR (diazóxido colina) para el Síndrome de Prader-Willi en la próxima conferencia ENDO 2025 en San Francisco. Las presentaciones serán realizadas por la Dra. Ashley Shoemaker del Vanderbilt University Medical Center.
La primera presentación, que será oral el 14 de julio de 2025, abordará los resultados glucémicos del medicamento durante un período de 4 años. La segunda presentación, en formato póster, se centrará en caracterizar el edema periférico en pacientes durante la administración a largo plazo de 4,5 años.
Soleno Therapeutics (NASDAQ: SLNO)는 다가오는 샌프란시스코 ENDO 2025 학회에서 프래더-윌리 증후군 치료제 VYKAT™ XR(디아조폭사이드 콜린)에 관한 두 건의 발표를 진행한다고 발표했습니다. 발표는 애슐리 슈메이커 박사(Vanderbilt University Medical Center)가 맡습니다.
첫 번째 발표는 2025년 7월 14일 구두 발표로, 약물의 4년간 혈당 조절 결과를 다룹니다. 두 번째 포스터 발표는 4.5년간 장기 투여 중인 환자들의 말초 부종 특성을 집중적으로 설명할 예정입니다.
Soleno Therapeutics (NASDAQ : SLNO) a annoncé deux présentations portant sur leur médicament VYKAT™ XR (diazoxide choline) pour le syndrome de Prader-Willi lors de la prochaine conférence ENDO 2025 à San Francisco. Les présentations seront réalisées par la Dr Ashley Shoemaker du Vanderbilt University Medical Center.
La première présentation, sous forme orale le 14 juillet 2025, portera sur les résultats glycémiques du médicament sur une période de 4 ans. La seconde présentation, au format poster, se concentrera sur la caractérisation de l’œdème périphérique chez les patients lors d’une administration à long terme sur 4,5 ans.
Soleno Therapeutics (NASDAQ: SLNO) gab zwei Präsentationen zu ihrem Medikament VYKAT™ XR (Diazoxid-Cholin) für das Prader-Willi-Syndrom auf der bevorstehenden ENDO 2025 Konferenz in San Francisco bekannt. Die Präsentationen werden von Dr. Ashley Shoemaker vom Vanderbilt University Medical Center gehalten.
Die erste Präsentation, eine mündliche Vorstellung am 14. Juli 2025, wird die glykämischen Ergebnisse des Medikaments über einen Zeitraum von 4 Jahren behandeln. Die zweite Präsentation im Posterformat konzentriert sich auf die Charakterisierung von peripherem Ödem bei Patienten während der Langzeitanwendung über 4,5 Jahre.
- None.
- None.
REDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets, previously known as DCCR, have been selected for presentation at the Annual Meeting of the Endocrine Society (ENDO 2025), which is being held July 12-15, 2025, in San Francisco, CA.
Details of the presentations are as follows:
| Title: | The Glycemic Outcomes of Diazoxide Choline Extended-Release (DCCR) Tablets for Administered for Hyperphagia in Individuals with Prader-Willi Syndrome Over 4 Years |
| Format: | Oral Presentation |
| Session: | OR35 – Adipose Tissue, Appetite, and Obesity: Fat and Full: Adipocyte Signaling, Appetite Regulation, and Metabolic Control |
| Date/Time: | Monday, July 14, 2025, 2:45pm-3:00pm PT (5:45pm-6:00pm ET) |
| Presenter: | Ashley Shoemaker, MD, MSCI, Associate Professor of Pediatrics, Pediatric Endocrinology, Vanderbilt University Medical Center |
| Title: | Characterization of Peripheral Edema in Individuals with Prader-Willi Syndrome During Long-term Administration of Diazoxide Choline Extended-Release Tablet (DCCR) Over 4.5 Years |
| Format: | Poster presentation |
| Session: | P104 - Adipose Tissue, Appetite, and Obesity: Decoding Appetite: Mechanisms, Modulation, and Metabolic Implications |
| Date/Time: | Monday, July 14, 2025, 12:00pm-1:30pm PT (3:00pm-4:30pm ET) |
| Presenter: | Ashley Shoemaker, MD, MSCI, Associate Professor of Pediatrics, Pediatric Endocrinology, Vanderbilt University Medical Center |
About PWS
Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease.
About VYKAT XR
VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.
VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).
IMPORTANT SAFETY INFORMATION
Contraindications
Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
Warnings and Precautions
Hyperglycemia
Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.
Risk of Fluid Overload
Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
Adverse Reactions
The most common adverse reactions (incidence ≥
Please see the full Prescribing Information, including Medication Guide.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Media Contact:
media@soleno.life
FAQ
When will Soleno Therapeutics (SLNO) present at ENDO 2025?
What topics will SLNO present about VYKAT XR at ENDO 2025?
Who will present the SLNO data at ENDO 2025?
Where will the ENDO 2025 conference featuring SLNO's presentations take place?
